114027
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
OPRM1 A118G 多态性与奥丹司琼在腹腔镜妇科手术后恶心呕吐疗效的关系：一项回顾性队列研究
Authors Zhao X, Yu Q, Yu G, Liu C, Feng Z, Zhang W
Received 4 July 2025
Accepted for publication 17 November 2025
Published 25 December 2025 Volume 2025:21 Pages 1821—1832
DOI https://doi.org/10.2147/TCRM.S551616
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Professor Garry Walsh
Xu Zhao,1,* Qingqing Yu,2,* Guanling Yu,2 Chengxiao Liu,1 Zunsai Feng,1 Wenjia Zhang1
1Department of Anesthesiology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, People’s Republic of China; 2State Key Laboratory of Reproductive Medicine and Offspring Health, Center for Reproductive Medicine, Institute of Women, Children and Reproductive Health, Shandong University, Jinan, Shandong, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Wenjia Zhang, Department of Anesthesiology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, 250021, People’s Republic of China, Tel +86-18615201505, Email wjzhang@email.sdfmu.edu.cn
Background: The OPRM1 A118G polymorphism has been implicated in modulating susceptibility to postoperative nausea and vomiting (PONV). Ondansetron, a 5-HT3 receptor antagonist, is widely utilized for PONV prophylaxis; however, whether its efficacy is influenced by OPRM1 A118G polymorphism remains unclear.
Methods: We conducted a retrospective cohort study including patients undergoing laparoscopic gynecological surgery between January 2019 and December 2024; propensity score matching was used to adjust for confounders. OPRM1 A118G genotypes (AA, AG, GG) were analyzed through polymerase chain reaction and sequencing. PONV incidence and severity were assessed using the Visual Analog Scale (VAS) at various postoperative time points.
Results: The Ondansetron group had significantly lower PONV incidence within 2 hours (38.82% vs 56.98%, p = 0.0174) and 2 ~ 24 hours (8.24% vs 19.77%, p = 0.0300). The OPRM1 A118G polymorphism was associated with higher PONV risk, particularly in patients with the AG/GG genotypes in the control group. In the Ondansetron group, the association was significant only within 2 hours (p = 0.0460).
Conclusion: The OPRM1 A118G polymorphism is associated with an increased risk of early PONV, particularly in patients with the G allele, which has been related to reduced μ-opioid receptor sensitivity and increased opioid requirements, thereby predisposing patients to a higher PONV risk. Ondansetron significantly reduces PONV incidence and severity, especially in patients with higher genetic susceptibility.
Keywords: postoperative nausea and vomiting, OPRM1, A118G, ondansetron
1Department of Anesthesiology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, People’s Republic of China; 2State Key Laboratory of Reproductive Medicine and Offspring Health, Center for Reproductive Medicine, Institute of Women, Children and Reproductive Health, Shandong University, Jinan, Shandong, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Wenjia Zhang, Department of Anesthesiology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, 250021, People’s Republic of China, Tel +86-18615201505, Email wjzhang@email.sdfmu.edu.cn
Background: The OPRM1 A118G polymorphism has been implicated in modulating susceptibility to postoperative nausea and vomiting (PONV). Ondansetron, a 5-HT3 receptor antagonist, is widely utilized for PONV prophylaxis; however, whether its efficacy is influenced by OPRM1 A118G polymorphism remains unclear.
Methods: We conducted a retrospective cohort study including patients undergoing laparoscopic gynecological surgery between January 2019 and December 2024; propensity score matching was used to adjust for confounders. OPRM1 A118G genotypes (AA, AG, GG) were analyzed through polymerase chain reaction and sequencing. PONV incidence and severity were assessed using the Visual Analog Scale (VAS) at various postoperative time points.
Results: The Ondansetron group had significantly lower PONV incidence within 2 hours (38.82% vs 56.98%, p = 0.0174) and 2 ~ 24 hours (8.24% vs 19.77%, p = 0.0300). The OPRM1 A118G polymorphism was associated with higher PONV risk, particularly in patients with the AG/GG genotypes in the control group. In the Ondansetron group, the association was significant only within 2 hours (p = 0.0460).
Conclusion: The OPRM1 A118G polymorphism is associated with an increased risk of early PONV, particularly in patients with the G allele, which has been related to reduced μ-opioid receptor sensitivity and increased opioid requirements, thereby predisposing patients to a higher PONV risk. Ondansetron significantly reduces PONV incidence and severity, especially in patients with higher genetic susceptibility.
Keywords: postoperative nausea and vomiting, OPRM1, A118G, ondansetron